Literature DB >> 34025099

Medical and Revascularization Management of Stable Ischemic Heart Disease: An Overview.

Qais Radaideh1,2, Nicolas W Shammas1,2, Ghassan E Daher3, Rayan Jo Rachwan4.   

Abstract

Stable ischemic heart disease (SIHD) affects approximately 10 million Americans with 500,000 new cases diagnosed each year. Patients with SIHD are primarily managed in the outpatient setting with aggressive cardiovascular risk factor modification via medical therapy and lifestyle changes. Currently, this approach is considered as the mainstay of treatment. The recently published ISCHEMIA trial has established the noninferiority of medical therapy in comparison to coronary revascularization in patients with moderate to severe ischemia. Percutaneous coronary intervention is currently recommended for patients with significant left main disease, large ischemic myocardial burden, and patients with severe refractory angina despite maximal medical therapy. International College of Angiology. This article is published by Thieme.

Entities:  

Keywords:  functional flow reserve; intravascular ultrasound; medical therapy; primary outcome; revascularization; stable ischemic heart disease

Year:  2021        PMID： 34025099      PMCID： PMC8128484          DOI： 10.1055/s-0040-1722739

Source DB:  PubMed          Journal:  Int J Angiol        ISSN： 1061-1711


  47 in total

Review 1.  Revascularization in stable coronary disease: evidence and uncertainties.

Authors:  Demosthenes G Katritsis; Daniel B Mark; Bernard J Gersh
Journal:  Nat Rev Cardiol       Date:  2018-07       Impact factor: 32.419

Review 2.  2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.

Authors:  Stephan D Fihn; James C Blankenship; Karen P Alexander; John A Bittl; John G Byrne; Barbara J Fletcher; Gregg C Fonarow; Richard A Lange; Glenn N Levine; Thomas M Maddox; Srihari S Naidu; E Magnus Ohman; Peter K Smith
Journal:  J Am Coll Cardiol       Date:  2014-07-28       Impact factor: 24.094

3.  SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.

Authors:  Thomas A Zelniker; Stephen D Wiviott; Itamar Raz; Kyungah Im; Erica L Goodrich; Marc P Bonaca; Ofri Mosenzon; Eri T Kato; Avivit Cahn; Remo H M Furtado; Deepak L Bhatt; Lawrence A Leiter; Darren K McGuire; John P H Wilding; Marc S Sabatine
Journal:  Lancet       Date:  2018-11-10       Impact factor: 79.321

Review 4.  Mechanisms of plaque formation and rupture.

Authors:  Jacob Fog Bentzon; Fumiyuki Otsuka; Renu Virmani; Erling Falk
Journal:  Circ Res       Date:  2014-06-06       Impact factor: 17.367

5.  Predictors, Trends, and Outcomes (Among Older Patients ≥65 Years of Age) Associated With Beta-Blocker Use in Patients With Stable Angina Undergoing Elective Percutaneous Coronary Intervention: Insights From the NCDR Registry.

Authors:  Apurva A Motivala; Valay Parikh; Matthew Roe; David Dai; J Dawn Abbott; Abhiram Prasad; Debabrata Mukherjee
Journal:  JACC Cardiovasc Interv       Date:  2016-08-22       Impact factor: 11.195

6.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

7.  A prospective natural-history study of coronary atherosclerosis.

Authors:  Gregg W Stone; Akiko Maehara; Alexandra J Lansky; Bernard de Bruyne; Ecaterina Cristea; Gary S Mintz; Roxana Mehran; John McPherson; Naim Farhat; Steven P Marso; Helen Parise; Barry Templin; Roseann White; Zhen Zhang; Patrick W Serruys
Journal:  N Engl J Med       Date:  2011-01-20       Impact factor: 91.245

8.  Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.

Authors:  Deepak L Bhatt; Keith A A Fox; Werner Hacke; Peter B Berger; Henry R Black; William E Boden; Patrice Cacoub; Eric A Cohen; Mark A Creager; J Donald Easton; Marcus D Flather; Steven M Haffner; Christian W Hamm; Graeme J Hankey; S Claiborne Johnston; Koon-Hou Mak; Jean-Louis Mas; Gilles Montalescot; Thomas A Pearson; P Gabriel Steg; Steven R Steinhubl; Michael A Weber; Danielle M Brennan; Liz Fabry-Ribaudo; Joan Booth; Eric J Topol
Journal:  N Engl J Med       Date:  2006-03-12       Impact factor: 91.245

9.  Fractional flow reserve-guided PCI for stable coronary artery disease.

Authors:  Bernard De Bruyne; William F Fearon; Nico H J Pijls; Emanuele Barbato; Pim Tonino; Zsolt Piroth; Nikola Jagic; Sven Mobius-Winckler; Gilles Rioufol; Nils Witt; Petr Kala; Philip MacCarthy; Thomas Engström; Keith Oldroyd; Kreton Mavromatis; Ganesh Manoharan; Peter Verlee; Ole Frobert; Nick Curzen; Jane B Johnson; Andreas Limacher; Eveline Nüesch; Peter Jüni
Journal:  N Engl J Med       Date:  2014-09-01       Impact factor: 91.245

10.  A randomized trial of therapies for type 2 diabetes and coronary artery disease.

Authors:  Robert L Frye; Phyllis August; Maria Mori Brooks; Regina M Hardison; Sheryl F Kelsey; Joan M MacGregor; Trevor J Orchard; Bernard R Chaitman; Saul M Genuth; Suzanne H Goldberg; Mark A Hlatky; Teresa L Z Jones; Mark E Molitch; Richard W Nesto; Edward Y Sako; Burton E Sobel
Journal:  N Engl J Med       Date:  2009-06-07       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.